Adavosertib
(AZD1775)Phase 2Small molecule
AstraZenecaAZD1775 is an experimental cancer drug being tested to treat various types of cancer by targeting a protein that helps cancer cells survive and divide.[1] Adavosertib is currently being investigated across 7 indications[3], with its most advanced program in Phase 2.[1]
Adavosertib is one of 121 small molecule programs targeting Clinical Stage III Esophageal Adenocarcinoma AJCC v8. It is currently in Phase 2.
7
Indications
27
Total Trials
9
Active Trials
120
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
118 competitors in Bladder Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Tecentriq
RochePhase 3
Imfinzi
AstraZenecaPhase 3
Trexall
Jazz PharmaceuticalsPhase 3
Padcev
PfizerPhase 3
Imjudo
AstraZenecaPhase 3
Gemzar
GGynecologic Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Lung Cancer4 trials
Small Cell Lung Cancer2 trials
Advanced Lymphoma2 trials
Head and Neck Cancer1 trial
Breast Cancer1 trial
CISPLATIN + AZD-1775 In Breast Cancer
Completed·—·Phase 2·NCT03012477·34 enrolled
17 more indications
Gastric Adenocarcinoma1 trial
Advanced Solid Tumours1 trial
Solid Tumours1 trial
Bladder Cancer1 trial
Refractory Solid Tumors1 trial
Pancreatic Cancer1 trial
Metastatic Colorectal Cancer1 trial
Cisplatin1 trial
Advanced or Metastatic Solid Tumour1 trial
Ovarian Brenner Tumor1 trial
Uterine Cancer1 trial
Clear Cell Renal Cell Carcinoma1 trial
Pediatric Cancer1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AZD1775. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company